Work

Supplementary Figure S7 from Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies

Year: 2023
Type: supplementary-materials
Abstract: Supplemental Figure 7. Quantification of immune cell composition in selected tumors determined by immunofluorescence multi-plex assay.
Language: English
Subfield: Biotechnology
Open Access status: gold
OpenAlex ID: W4378215127
Cites:
Cited by:
Related to: